welcome first quarter financial result conference call operator instruction please note event record would like turn conference please ahead senior vice president investor relation thank operator good afternoon everyone please welcome first quarter financial result conference call afternoon issue press release result press release support slide available website investor section event presentation page speaker today call president chief executive officer chief financial officer chip executive vice president commercial chief medical officer follow prepare remark open line question keep call hour operator instruction today conference call include forward look statement regard future anticipate event result include company financial outlook anticipate product sale revenue expense future development relate legal matter potential clinical regulatory milestone include data readout regulatory submission potential market reimbursement approval actual result development differ materially project imply forward look statement factor cause difference include difficulty forecast sale revenue expense impact relate pandemic uncertainty associate legal dispute pharmaceutical development regulatory approval process information risk uncertainty face contain caption risk factor include company annual report form year file security exchange commission company subsequent report file turn call president chief executive officer thank good afternoon everyone welcome first quarter call please report total revenue million first quarter include product sale million represent growth first quarter last year growth reflect strong product sale across commercial brand look deliver continue innovation develop transformative therapy remain focus strategic priority first priority work maximize global potential product commercial performance robust clinical development program design support future label expansion also leverage strategic partnership begin become standard care previously treat metastatic urothelial cancer earlier month partner secure approval previously treat locally advance metastatic urothelial cancer approval base trial notably impressive overall survival benefit mark important milestone patient region previously limit treatment option offer poor survival rate previously secure approval continue progress regulatory submission across pacific engage individual country authority secure reimbursement take year depend country robust clinical development program span monotherapy combination earlier line therapy cohort data anticipate second half year along data trial could potentially support accelerate approval patient first line metastatic urothelial cancer next year also evaluate combination muscle invasive bladder cancer monotherapy nonmuscle invasive disease represent area significant unmet need large addressable patient population become important option treatment second later line positive breast cancer patient without brain metastasis overall survival data inclusion treatment guideline reflect exceptional clinical value deliver strong result quarter although continue expect competitive challenge year factor annual guidance work enable additional launch strategic collaboration merck expand reach outside broad development program include clinical trial positive breast cancer colorectal cancer gastric cancer amplify mutant tumor data phase trial expect second half year could potentially support accelerate approval next year patient express colorectal cancer although relatively modest patient population represent high unmet medical need exist approve colorectal cancer therapy offer limit efficacy tissue factor target approve recurrent metastatic cervical cancer patient represent important therapy disease historically poor outcome launch last collaboration strong uptake drive differentiate clinical data positive reception oncologist community focus commercial execution present promise combination data earlier line cervical cancer represent clinical advancement much larger market opportunity provide detail clinical development program design maximize future opportunity cervical cancer solid tumor support global regulatory application approve country regimen standard care frontline lymphoma peripheral cell lymphoma decade first launch partner continue bring important medicine patient around globe groundbreaking overall survival data phase trial newly diagnose advance lymphoma demonstrate therapeutic value importance patient addition phase child oncology group study demonstrate improvement event free survival high risk pediatric patient lymphoma data phase pediatric data present submit year lastly progress comprehensive clinical development program maximize potential benefit patient second strategic priority advance deep diverse pipeline look bring additional drug market come year disitamab vedotin late stage novel utilize vedotin base technology active across broad range express solid tumor demonstrate rapid internalization clinical development program prioritize monotherapy combination approach breast bladder gastric cancer recently initiate pivotal trial previously treat metastatic urothelial cancer intend support accelerate approval turn earlier stage pipeline advance several novel validate target also four program proprietary sugar engineer antibody technology overall progress program product across pipeline range solid tumor hematologic malignancy collaborator also make important progress program utilize technology recently report recommend commission approval combination therapy frontline diffuse large cell lymphoma commercialize patient relapse multiple myeloma advance several clinical trial grant breakthrough therapy designation vedotin base data phase study small cell lung cancer look future plan continue build upon four commercial product advance deep diverse pipeline expand geographic footprint strategic partnership include recent collaboration base cash position approximately billion debt strongly position utilize edge innovation make positive impact life people cancer today tomorrow next turn call financial result chip provide update commercial performance detail clinical development activity pipeline chief financial officer thank thank everyone join call afternoon briefly summarize financial result quarter align expectation reflect significant progress across business total revenue million first quarter represent growth first quarter last year include product sale million increase first quarter drive strong growth first quarter sale also include million sale another company combination clinical trial conduct factor guidance additionally first quarter product sale include contribution launch third quarter fourth approve drug royalty revenue first quarter increase slightly million compare first quarter royalty primarily drive sale outside lesser degree royalty sale expect royalty decrease fourth quarter last year royalty rate sale reset begin year range teen collaboration revenue million first quarter include upfront payment collaboration sign march profit share contribution sale collaboration activity create degree quarterly variability collaboration revenue follow recent approval expect begin report profit share amount next year sale sale first quarter increase million include product sale royalty four brand profit share amount collaboration partner noncash amortization acquire technology expense increase million first quarter reflect continue investment across deep diverse pipeline maximize potential approve product pipeline program expense increase million first quarter drive commercialization effort launch investment support ongoing country launch across strong start please financial result mind maintain financial guidance provide call chip provide additional detail commercial performance outlook chip executive vice president commercial thank please provide update commercial performance quarterly record million cover four approve brand first quarter sale million increase first quarter exclude million clinical trial supplier order growth first quarter last year first year market become standard care post checkpoint look forward potential label expansion frontline cisplatin ineligible patient also excite recent approval look forward work collaborator bring important therapy patient move first quarter sale million increase first quarter recall outlook assume impact competitive pressure anticipate launch second line inclusion guideline pathway remain expectation despite modest impact first quarter approval continue anticipate shift regimen sequence increase delay patient flow third line plus mostly promotional effort focus strong value proposition especially patient involvement sale continue grow first quarter look forward gain reimbursement additional country year first quarter sale million increase first quarter drive awareness positive overall survival data trial line data announce receive look forward move full data oral presentation finally sale million quarter initial indication modest opportunity please positive reception physician patient important treatment option hand call chief medical officer thank chip good afternoon everyone happy share recent clinical development update approve medicine pipeline begin please recent approval base overall survival advantage previously treat patient metastatic urothelial cancer demonstrate trial study positive prespecified interim analysis plan present important long term outcome base additional month follow frontline metastatic evaluate combination study first study cohort patient ineligible cisplatin therapy second phase global trial include cisplatin eligible ineligible patient track complete enrollment year look muscle invasive bladder cancer together merck advance phase trial combination perioperative treatment trial test usage cisplatin eligible patient cisplatin ineligible patient recent meet present promise monotherapy data neoadjuvant people suspect ineligible data important understand impact monotherapy context ongoing combination trial furthermore progress effort nonmuscle invasive bladder cancer phase trial investigate single agent administer intravesically nonresponsive patient meet earlier month present preclinical data model show minimal local systemic toxicity along evidence antitumor activity beyond bladder cancer continue monotherapy basket trial express solid tumor turn please announce recently first patient study evaluate frontline maintenance positive metastatic breast cancer patient receive trastuzumab pertuzumab trastuzumab pertuzumab alone completion taxane component combination therapy despite excellent result obtain standard care treatment patient remain risk relapse death include risk relapse brain cancer expect report line result phase trial second half year potential accelerate approval unite state next year study trastuzumab treatment patient previously treat metastatic positive colorectal cancer first line recently initiate global phase trial compare trastuzumab standard chemotherapy chemotherapy alone trial intend serve confirmatory trial positive receive accelerate approval unite state also support future global submission additionally study combination trastuzumab basket trial solid tumor move receive accelerate approval unite state treatment patient recurrent metastatic cervical cancer disease progression chemotherapy phase monotherapy trial cervical cancer intend serve confirmatory trial unite state facilitate global regulatory application look move earlier line metastatic recurrent cervical cancer present frontline combination data trial oral presentation study also expand investigate frontline multi drug combination include carboplatin without bevacizumab beyond cervical cancer continue study malignancy monotherapy combination platinum contain chemotherapy ongoing phase study evaluate multiple solid tumor include patient squamous cell carcinoma head neck recently present encourage monotherapy data patient expand trial explore combination chemotherapy frontline head neck cancer turn extremely please important phase trial newly diagnose lymphoma patient select presentation first data show combination significantly improve overall survival compare patient advance lymphoma show reduce risk death hazard ratio value second presentation data phase child oncology group study pediatric patient high risk lymphoma study meet primary endpoint superior three year event free survival plus chemotherapy compare chemotherapy regimen include bleomycin plan submit supplemental trial year turn disitamab vedotin recently begin patient registrational phase monotherapy trial second line express metastatic urothelial cancer obtain positive result study could potentially support accelerate approval unite state also plan initiate additional registration study bladder cancer breast cancer next several month also consider development express solid tumor gastric cancer like briefly mention early stage pipeline currently evaluate grow number drug candidate phase clinical trial across range solid tumor hematologic malignancy earlier month present promise preclinical data newest clinical stage program vedotin target immune checkpoint express across tumor include breast ovarian endometrial cancer limit normal tumor expression detail robust antitumor activity immunomodulatory activity induction cell death also disclose preclinical antitumor activity novel vedotin target central express across solid tumor include ovarian endometrial gastric small cell lung cancer recently first patient phase trial hand call president chief executive officer thank turn would like comment ongoing legal proceed jury recently find patent award damage million represent royalty past sale unite state verdict intend request court award royalty future sale expiry patent enhance damage attorney anticipate decision court future royalty later year relate matter patent trademark office grant request institute post grant review proceed bring certain claim patent intend vigorously defend separately engage arbitration ownership certain technology several product candidate expect decision arbitration important defend intellectual property continue drive groundbreaking innovation develop transformative therapy patient need close expect achieve many important milestone include important clinical data readout global commercial progress advance across pipeline open question operator please open line